Edition:
India

Caladrius Biosciences Inc (CLBS.OQ)

CLBS.OQ on NASDAQ Stock Exchange Capital Market

1.61USD
1:30am IST
Change (% chg)

$-0.10 (-5.85%)
Prev Close
$1.71
Open
$1.70
Day's High
$1.71
Day's Low
$1.59
Volume
13,872
Avg. Vol
97,110
52-wk High
$3.58
52-wk Low
$1.15

Latest Key Developments (Source: Significant Developments)

Caladrius Biosciences Announces Registration Of HONEDRA Trademark, New Patent In Japan
Wednesday, 9 Sep 2020 

Sept 9 (Reuters) - Caladrius Biosciences Inc ::CALADRIUS BIOSCIENCES ANNOUNCES REGISTRATION OF HONEDRA TRADEMARK AND NEW PATENT IN JAPAN.CALADRIUS BIOSCIENCES INC - HONEDRA ANTICIPATED TO BE APPROVED AND COMMERCIALIZED IN JAPAN AS EARLY AS MID-2022.  Full Article

Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Thursday, 23 Apr 2020 

April 23 (Reuters) - Caladrius Biosciences Inc ::CALADRIUS BIOSCIENCES ANNOUNCES $5.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES.CALADRIUS BIOSCIENCES INC - AGREEMENTS FOR ISSUANCE AND SALE OF 2.2 MILLION SHARES OF COMMON STOCK AT $2.3125 PER SHARE.CALADRIUS BIOSCIENCES INC - INTENDS TO USE NET PROCEEDS FROM OFFERING FOR ADVANCEMENT OF ITS CD34+ TECHNOLOGY-BASED CLINICAL PROGRAMS.  Full Article

Caladrius Biosciences Reports Positive Results For CLBS16 From Escape-CMD Trial
Sunday, 17 Nov 2019 

Nov 16 (Reuters) - Caladrius Biosciences Inc ::CALADRIUS BIOSCIENCES REPORTS POSITIVE RESULTS FOR CLBS16 FROM ESCAPE-CMD TRIAL AT AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2019.TRIAL INVESTIGATORS OBSERVED PATIENTS HAD HIGH (P=0.0087) INCREASE IN CORONARY FLOW RESERVE AFTER SINGLE INTRACORONARY ADMINISTRATION OF CLBS16.SINGLE ADMINISTRATION OF CLBS16 RESULTED IN STATISTICALLY SIGNIFICANT IMPROVEMENTS IN MEASURES OF PATIENT SYMPTOMS AND FUNCTION.TRIAL COMPLETED ENROLLMENT OF TARGETED 20 PATIENTS IN MAY OF 2019.RESULTS FROM SIX-MONTH FOLLOW-UP OF REMAINING TREATED PATIENTS WILL BE AVAILABLE BY YEAR-END 2019..  Full Article

BRIEF-Caladrius Biosciences Files Prospectus Relates To Resale Of Up To 2.1 Mln Common Shares By Selling Stockholders - SEC Filing

* CALADRIUS BIOSCIENCES FILES PROSPECTUS RELATES TO RESALE OF UP TO 2.1 MILLION COMMON SHARES BY SELLING STOCKHOLDERS - SEC FILING Source text: https://bit.ly/2YgzrvR Further company coverage: